Ask AI
Tx Selection and Optimization in MCL

CME

Treatment Selection and Optimization in MCL From a European Union Perspective

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 15, 2025

Expiration: October 14, 2025

Activity

Progress
1 2
Course Completed

Introduction

In this module, Mats Jerkeman, MD, PhD provides a European perspective on the current treatment algorithm, guidelines, and evidence-based approaches for the optimal integration of available treatments into the management of patients with mantle cell lymphoma (MCL) with careful consideration of patients’ age, fitness level, presence of high-risk features, preexisting comorbidities, and concomitant medications.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with MCL do you provide care for in a typical month?

In your current practice, what would you recommend as the optimal first-line treatment for this 61-year-old man?

At this time, which treatment would you initiate for this 72-year-old patient?

Which of the following would you educate this patient to avoid for managing headaches that he may experience when starting treatment with acalabrutinib?

In your current practice, what would you recommend as the optimal next-line treatment for this 79-year-old patient?